

Carol R Bradford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3721117/publications.pdf>

Version: 2024-02-01

117
papers

5,184
citations

87723

38
h-index

95083

68
g-index

117
all docs

117
docs citations

117
times ranked

6427
citing authors

#	ARTICLE	IF	CITATIONS
1	Honesty and Transparency, Indispensable to the Clinical Missionâ€”Part II. Otolaryngologic Clinics of North America, 2022, 55, 63-82.	0.5	8
2	Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials. Clinical and Translational Radiation Oncology, 2022, 33, 30-36.	0.9	0
3	Small molecule profiling to define synergistic <scp>EGFR</scp> inhibitor combinations in head and neck squamous cell carcinoma. Head and Neck, 2022, 44, 1192-1205.	0.9	5
4	Operational Constraints and Gender Biases: A Qualitative Analysis of Physician Parenting Experiences. Women S Health Reports, 2022, 3, 297-306.	0.4	1
5	Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel <scp>Bclâ€xL</scp> inhibitor. Head and Neck, 2022, , .	0.9	2
6	Prioritizing Diversity in Otolaryngologyâ€”Head and Neck Surgery: Starting a Conversation. Otolaryngology - Head and Neck Surgery, 2021, 164, 229-233.	1.1	40
7	Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery. Oral Oncology, 2021, 113, 105034.	0.8	3
8	<scp>Longâ€term</scp> neck and shoulder function among survivors of oropharyngeal squamous cell carcinoma treated with chemoradiation as assessed with the neck dissection impairment index. Head and Neck, 2021, 43, 1621-1628.	0.9	2
9	Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal Cancer. Oncologist, 2021, 26, 676-684.	1.9	8
10	Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. Oral Oncology, 2021, 121, 105332.	0.8	15
11	Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy. Laryngoscope, 2020, 130, 1707-1714.	1.1	4
12	Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncology, 2020, 101, 104521.	0.8	48
13	Patient and Provider Perspectives Regarding Enrollment in Head and Neck Cancer Research. Otolaryngology - Head and Neck Surgery, 2020, 162, 73-78.	1.1	10
14	The risk of second primary tumors in head and neck cancer: A systematic review. Head and Neck, 2020, 42, 456-466.	0.9	47
15	Impact of extrinsic tongue muscle invasion on stage migration in AJCC 8th edition staging of oral cavity carcinoma. Oral Oncology, 2020, 110, 104888.	0.8	1
16	Upholding the Tripartite Mission in Times of Crisis: Purpose and Perseverance in the COVID-19 Pandemic. Otolaryngology - Head and Neck Surgery, 2020, 163, 54-59.	1.1	7
17	Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy. European Archives of Oto-Rhino-Laryngology, 2020, 277, 2085-2093.	0.8	3
18	â€œMy Research Is Their Business, but I'm Not Their Businessâ€”Patient and Clinician Perspectives on Commercialization of Precision Oncology Data. Oncologist, 2020, 25, 620-626.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Prognostic factors in laryngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 74-81.	0.6	44
20	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. <i>Head and Neck</i> , 2020, 42, 1728-1737.	0.9	6
21	Speech and swallowing outcomes after laryngectomy for the dysfunctional irradiated larynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1459-1465.	0.8	13
22	<scp>COVID</scp>â€19 pandemic: Effects and evidenceâ€based recommendations for otolaryngology and head and neck surgery practice. <i>Head and Neck</i> , 2020, 42, 1259-1267.	0.9	218
23	Parathyroid cancer: An update. <i>Cancer Treatment Reviews</i> , 2020, 86, 102012.	3.4	58
24	Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines. <i>Nagoya Journal of Medical Science</i> , 2020, 82, 519-531.	0.6	0
25	Contemporary management of primary parapharyngeal space tumors. <i>Head and Neck</i> , 2019, 41, 522-535.	0.9	61
26	Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 423-428.	0.9	11
27	Work-Life Balance Among Head and Neck Surgeonsâ€ Seeking Visionary Leadership From Everywhere. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 458.	1.2	3
28	Elective Paratracheal Lymph Node Dissection in Salvage Laryngectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2542-2548.	0.7	8
29	The role of age in treatmentâ€related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , 2019, 41, 2410-2429.	0.9	24
30	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	0.9	28
31	Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 213-220.	2.0	36
32	Understanding Interactions of Smoking on Prognosis of HPV-Associated Oropharyngeal Cancers. <i>Advances in Therapy</i> , 2018, 35, 255-260.	1.3	16
33	Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome. <i>Advances in Therapy</i> , 2018, 35, 153-160.	1.3	52
34	Hypothyroidism and Wound Healing After Salvage Laryngectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1288-1295.	0.7	26
35	Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 77, 83-89.	0.8	53
36	In reply: Management of thin melanoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 536-536.	0.8	0

#	ARTICLE	IF	CITATIONS
37	T4 Laryngeal Cancer With Good Function: Should We Be Reluctant to Treat Without Surgery?. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1400-1403.	0.4	5
38	Management of the facial nerve in parotid cancer: preservation or resection and reconstruction. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2615-2626.	0.8	57
39	The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma. Cancers, 2018, 10, 267.	1.7	81
40	Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. Auris Nasus Larynx, 2017, 44, 18-25.	0.5	32
41	Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 355.	1.2	32
42	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	0.9	34
43	Positron emission tomography-CT prediction of occult nodal metastasis in recurrent laryngeal cancer. Head and Neck, 2017, 39, 980-987.	0.9	17
44	Pathogenetic Analysis of Sinonasal Teratocarcinomas Reveal Actionable β -catenin Overexpression and a β -catenin Mutation. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 346-352.	0.4	34
45	Total versus superficial parotidectomy for stage III melanoma. Head and Neck, 2017, 39, 1665-1670.	0.9	14
46	Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngology - Head and Neck Surgery, 2017, 157, 625-630.	1.1	5
47	Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer. Otolaryngology - Head and Neck Surgery, 2017, 157, 432-438.	1.1	18
48	Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncology, 2017, 68, 5-8.	0.8	67
49	Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma. Head and Neck, 2017, 39, 2512-2518.	0.9	35
50	Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. Otolaryngology - Head and Neck Surgery, 2017, 157, 995-997.	1.1	7
51	Implementation of an Intramural Competitive Resident Research Grant. Otolaryngology - Head and Neck Surgery, 2017, 156, 1114-1118.	1.1	3
52	The natural history of thin melanoma and the utility of sentinel lymph node biopsy. Journal of Surgical Oncology, 2017, 116, 1185-1192.	0.8	18
53	Decision Making for Diagnosis and Management. Otolaryngologic Clinics of North America, 2017, 50, 783-792.	0.5	1
54	Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes and Cancer, 2016, 7, 182-200.	0.6	41

#	ARTICLE	IF	CITATIONS
55	Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. <i>Laryngoscope</i> , 2016, 126, E184-90.	1.1	12
56	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. <i>Oral Oncology</i> , 2016, 60, 32-40.	0.8	30
57	Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. <i>Head and Neck</i> , 2016, 38, E1646-52.	0.9	31
58	Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1074-1084.	0.9	259
59	Neurologic late effects associated with radiologic evidence of vertebral osteoradionecrosis after salvage laryngectomy: A syndrome associated with survivors of laryngeal and hypopharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1187-1193.	0.9	1
60	In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2016, 45, 26.	0.9	30
61	Occult Nodal Disease Prevalence and Distribution in Recurrent Laryngeal Cancer Requiring Salvage Laryngectomy. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 473-479.	1.1	45
62	IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence. <i>Neoplasia</i> , 2016, 18, 273-281.	2.3	23
63	Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 559.	1.2	37
64	Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , 2016, 14, 941-952.	1.5	43
65	Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2016, 120, 81-86.	0.3	50
66	Removing the Taboo on the Surgical Violation (Cut-Through) of Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 1010.	1.2	11
67	Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. <i>Laryngoscope</i> , 2016, 126, E292-E299.	1.1	20
68	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016, 38, E2151-8.	0.9	146
69	Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 155, 106-112.	1.1	8
70	Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 184-190.	0.9	35
71	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. <i>Investigational New Drugs</i> , 2016, 34, 481-489.	1.2	30
72	Update on primary head and neck mucosal melanoma. <i>Head and Neck</i> , 2016, 38, 147-155.	0.9	143

#	ARTICLE	IF	CITATIONS
73	Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. <i>Head and Neck</i> , 2016, 38, E459-67.	0.9	16
74	Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 313.	1.2	11
75	Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation. <i>Oral Oncology</i> , 2016, 54, 68-74.	0.8	15
76	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2877-2894.	0.8	22
77	NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas. <i>BMC Cancer</i> , 2015, 15, 825.	1.1	18
78	Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. <i>Head and Neck</i> , 2015, 37, 134-150.	0.9	106
79	Incidental Masticator Space Lesion in a Teenager. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 577.	1.2	0
80	When is chemotherapy in head and neck squamous cell carcinoma not indicated?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 781-787.	0.8	6
81	Epigenetic alterations in metastatic cutaneous carcinoma. <i>Head and Neck</i> , 2015, 37, 994-1001.	0.9	31
82	Neck spasm after chemoradiotherapy for head and neck cancer: Natural history and dosimetric correlates. <i>Head and Neck</i> , 2014, 36, 176-180.	0.9	7
83	Head and neck squamous cell carcinoma of unknown primary: Neck dissection and radiotherapy or definitive radiotherapy. <i>Head and Neck</i> , 2014, 36, 1589-1595.	0.9	34
84	Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. <i>Head and Neck</i> , 2014, 36, 617-623.	0.9	22
85	Efficacy of Induction Selection Chemotherapy vs Primary Surgery for Patients With Advanced Oral Cavity Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 134.	1.2	33
86	Chemoprophylaxis for Venous Thromboembolism in Otolaryngology. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 999.	1.2	70
87	Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 234-239.	0.8	68
88	Biomarkers in advanced larynx cancer. <i>Laryngoscope</i> , 2014, 124, 179-187.	1.1	40
89	Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio. <i>Translational Oncology</i> , 2014, 7, 479-483.	1.7	7
90	UM-SCC-103. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2014, 123, 662-672.	0.6	8

#	ARTICLE	IF	CITATIONS
91	The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014, 35, 226-232.	0.6	8
92	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 513-519.	0.8	62
93	High-Risk Human Papillomavirus Detection in Oropharyngeal, Nasopharyngeal, and Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 1320.	1.2	93
94	The Care of the Head and Neck Cancer Patient Is a Team Sport. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 337.	1.2	6
95	Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. <i>Oral Oncology</i> , 2012, 48, 918-922.	0.8	62
96	Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. <i>Cancer</i> , 2012, 118, 1040-1047.	2.0	79
97	Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results. <i>Journal of Clinical Oncology</i> , 2010, 28, 2732-2738.	0.8	305
98	Tobacco Use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence. <i>Clinical Cancer Research</i> , 2010, 16, 1226-1235.	3.2	271
99	Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer. <i>JAMA Otolaryngology</i> , 2008, 134, 363.	1.5	46
100	Incidence and Prognosis of Cutaneous Melanoma Involving the Head and Neck. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2628.	3.8	2
101	Targeting Apoptosis to Overcome Cisplatin Resistance: A Translational Study in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S106-S108.	0.4	27
102	Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm. <i>Journal of Clinical Oncology</i> , 2006, 24, 593-598.	0.8	240
103	Reversal of cisplatin resistance with a BH3 mimetic, (âˆš)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1096-1104.	1.9	116
104	Selective Neck Dissection Is an Option for Early Node-Positive Disease. <i>JAMA Otolaryngology</i> , 2004, 130, 1436.	1.5	8
105	P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. <i>Head and Neck</i> , 2003, 25, 654-661.	0.9	144
106	Development and Validation of the Neck Dissection Impairment Index. <i>JAMA Otolaryngology</i> , 2002, 128, 44.	1.5	135
107	Functional assessment using Constant's Shoulder Scale after modified radical and selective neck dissection. <i>Head and Neck</i> , 2002, 24, 432-436.	0.9	129
108	Free Tissue Reconstruction of the Hypopharynx After Organ Preservation Therapy: Analysis of Wound Complications. <i>Laryngoscope</i> , 2001, 111, 1192-1196.	1.1	61

#	ARTICLE	IF	CITATIONS
109	Pain, Quality of Life, and Spinal Accessory Nerve Status After Neck Dissection. <i>Laryngoscope</i> , 2000, 110, 620-626.	1.1	192
110	Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 1999, 121, 534-538.	1.1	65
111	Health Impact of Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 1999, 120, 852-859.	1.1	82
112	Expression of Human Papillomavirus 6 in Inverted Papilloma Arising in a Renal Transplant Recipient. <i>Laryngoscope</i> , 1998, 108, 115-119.	1.1	7
113	Planned Early Neck Dissection Before Radiation for Persistent Neck Nodes After Induction Chemotherapy. <i>Laryngoscope</i> , 1997, 107, 1129-1137.	1.1	14
114	Second Place "Resident Clinical Science Award 1995: Human Papillomavirus Types Important in Progression of Inverted Papilloma. <i>Otolaryngology - Head and Neck Surgery</i> , 1995, 113, 558-563.	1.1	57
115	Analysis of recurrence, complications, and functional results with free jejunal flaps. <i>Head and Neck</i> , 1994, 16, 149-154.	0.9	38
116	11p Deletions and breakpoints in squamous cell carcinoma: Association with altered reactivity with the UM-E7 antibody. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 272-282.	1.5	29
117	Squamous Carcinoma of the Head and Neck in Organ Transplant Recipients. <i>Laryngoscope</i> , 1990, 100, 190-194.	1.1	63